Literature DB >> 17961111

Plasma viral load threshold for sustaining intrahost HIV type 1 evolution.

Gonzalo Bello1, Concepción Casado, Virginia Sandonis, Tamara Alvaro-Cifuentes, Caio A Rodrigues Dos Santos, Soledad García, Carmen Rodríguez, Jorge Del Romero, José H Pilotto, Beatriz Grinsztejn, Valdilea G Veloso, Mariza G Morgado, Cecilio López-Galíndez.   

Abstract

The objective of the present study was to determine if natural suppression of plasma viremia below the detection limit of commercial assays (50-80 copies HIV-1 RNA/ml) can contain the HIV-1 evolution. HIV-1 quasispecies complexity in PBMC DNA was assessed in the env gene at two time points in 14 long-term nonprogressors (LTNPs). Sequence changes consistent with viral evolution was found in all patients with a median plasma RNA viral load >100 copies/ml. Evidence of low-level viral evolution was detected in two of four patients with intermittent viremia and a median plasma HIV-1 RNA load of >80 copies/ml. No significant evolution was observed in the three LTNPs with persistent viral suppression below the detection limit. Overall, a significant positive correlation (p < 0.001) was observed between viral evolution and plasma RNA viral load in the LTNPs analyzed. These results suggest that the detection limit of ultrasensitive viremia assays could represent an important threshold below which intrahost HIV-1 evolution does not occur.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17961111     DOI: 10.1089/aid.2007.0074

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

1.  Coreceptor usage, diversity, and divergence in drug-naive and drug-exposed individuals from Malawi, infected with HIV-1 subtype C for more than 20 years.

Authors:  Ishla Seager; Simon A Travers; Michael D Leeson; Amelia C Crampin; Neil French; Judith R Glynn; Grace P McCormack
Journal:  AIDS Res Hum Retroviruses       Date:  2014-07-29       Impact factor: 2.205

2.  Transmission selects for HIV-1 strains of intermediate virulence: a modelling approach.

Authors:  George Shirreff; Lorenzo Pellis; Oliver Laeyendecker; Christophe Fraser
Journal:  PLoS Comput Biol       Date:  2011-10-13       Impact factor: 4.475

Review 3.  CD4saurus Rex &HIVelociraptor vs. development of clinically useful immunological markers: a Jurassic tale of frozen evolution.

Authors:  Andrea De Maria; Andrea Cossarizza
Journal:  J Transl Med       Date:  2011-06-16       Impact factor: 5.531

Review 4.  Clinical management of HIV drug resistance.

Authors:  Karoll J Cortez; Frank Maldarelli
Journal:  Viruses       Date:  2011-04-14       Impact factor: 5.048

5.  Limited evolution of inferred HIV-1 tropism while viremia is undetectable during standard HAART therapy.

Authors:  Guinevere Q Lee; Winnie Dong; Theresa Mo; David J H F Knapp; Chanson J Brumme; Conan K Woods; Steve Kanters; Benita Yip; P Richard Harrigan
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

6.  Highly divergent patterns of genetic diversity and evolution in proviral quasispecies from HIV controllers.

Authors:  Suwellen S D de Azevedo; Diogo Gama Caetano; Fernanda H Côrtes; Sylvia L M Teixeira; Karina Dos Santos Silva; Brenda Hoagland; Beatriz Grinsztejn; Valdilea G Veloso; Mariza G Morgado; Gonzalo Bello
Journal:  Retrovirology       Date:  2017-05-02       Impact factor: 4.602

7.  The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients.

Authors:  Pedro Borrego; José Maria Marcelino; Cheila Rocha; Manuela Doroana; Francisco Antunes; Fernando Maltez; Perpétua Gomes; Carlos Novo; Helena Barroso; Nuno Taveira
Journal:  Retrovirology       Date:  2008-09-08       Impact factor: 4.602

8.  Next-generation sequencing analyses of the emergence and maintenance of mutations in CTL epitopes in HIV controllers with differential viremia control.

Authors:  Diogo Gama Caetano; Fernanda Heloise Côrtes; Gonzalo Bello; Sylvia Lopes Maia Teixeira; Brenda Hoagland; Beatriz Grinsztejn; Valdilea Gonçalves Veloso; Monick Lindenmeyer Guimarães; Mariza Gonçalves Morgado
Journal:  Retrovirology       Date:  2018-09-10       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.